Stephen T. Magill, MD, PhD, assistant professor of Neurological Surgery at Northwestern Medicine, discusses important clinical advances in the diagnosis and management of meningioma.
“Over the years, we have begun to develop a molecular gene panel that looks at gene expression changes and actually, with greater fidelity than methylation profiling and epigenetic changes, can predict meningioma recurrence and response to radiotherapy,” says Dr. Magill. “And that’s the first biomarker that anyone has developed to predict response to radiotherapy in meningioma.”
[ Ссылка ]
